36209-49-1

Basic information

• Product Name: 4-AMINO-5-(4-METHOXY-PHENYL)-4H-[1,2,4]TRIAZOLE-3-THIOL
• Synonyms: 4-amino-5-(4-methoxyphenyl)-2H-1,2,4-triazole-3-thione
• CAS NO: 36209-49-1
• Molecular Formula: C₉H₁₀N₄OS
• Molecular Weight: 222.27
• Mol File: 36209-49-1.mol
• Article Data: 40

Chemical Properties

• Boiling Point: 348°Cat760mmHg
• Flash Point: 164.2°C
• Appearance: /
• Density: 1.46g/cm³
• Vapor Pressure: 5.2E-05mmHg at 25°C
• Refractive Index: 1.711
• CAS DataBase Reference: 4-AMINO-5-(4-METHOXY-PHENYL)-4H-[1,2,4]TRIAZOLE-3-THIOL(CAS DataBase Reference)
• NIST Chemistry Reference: 4-AMINO-5-(4-METHOXY-PHENYL)-4H-[1,2,4]TRIAZOLE-3-THIOL(36209-49-1)
• EPA Substance Registry System: 4-AMINO-5-(4-METHOXY-PHENYL)-4H-[1,2,4]TRIAZOLE-3-THIOL(36209-49-1)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 36209-49-1(Hazardous Substances Data)

Usage

General Description

The chemical 4-AMINO-5-(4-METHOXY-PHENYL)-4H-[1,2,4]TRIAZOLE-3-THIOL, also known as AMPT, is a sulfur-containing heterocyclic compound with potential anticancer and antitumor properties. It is a member of the 1,2,4-triazole family and contains a thiol group. AMPT has been studied for its ability to inhibit the enzyme thymidylate synthase, which is important for DNA synthesis and repair. This inhibition can lead to the suppression of tumor cell growth, making it a potential candidate for cancer treatment. Additionally, AMPT has shown activity in inducing apoptosis (programmed cell death) in cancer cells, further supporting its potential as a therapeutic agent.

InChI:InChI=1/C9H10N4OS/c1-14-7-4-2-6(3-5-7)8-11-12-9(15)13(8)10/h2-5H,10H2,1H3,(H,12,15)

Upstream product

• 83511-12-0 acetic p-anisic anhydride 
• 10364-93-9 1-(4-methoxybenzoyl)-imidazole 
• 75-15-0 carbon disulfide 
• 100-09-4 4-methoxybenzoic acid 
• 121-98-2 methyl 4-methoxybenzoate 
• 2231-57-4 Thiocarbohydrazide 
• 23766-26-9 5?(4?methoxyphenyl)?1,3,4?oxadiazole?2?thiol 
• 3290-99-1 4-methoxybenzoic acid hydrazide 
• 85103-41-9 potassium N-(4-methoxybenzoyl)hydrazinecarbodithioate 
• 100-07-2 4-methoxy-benzoyl chloride 
• 451-82-1 (2-fluorophenyl)acetic acid 
• 116622-94-7 2-(2-fluorophenyl)acetohydrazide 
• 57486-67-6 methyl o-fluorophenylacetate 
• 94-30-4 ethyl 4-methoxybenzoate 

Downstream Products

• 420099-39-4 5-(4-Methoxy-phenyl)-4-{[1-(2-methoxy-phenyl)-meth-(E)-ylidene]-amino}-4H-[1,2,4]triazole-3-thiol 
• 1202208-33-0 C₁₈H₁₉N₅OS 
• 1293362-44-3 methyl 3-(3-(4-methoxyphenyl)-5-thioxo-1H-1,2,4-triazol-4-ylimino)cholanate 
• 1400796-58-8 methyl 3α-(2-(4-amino-3-(4-methoxyphenyl)-5-thioxo-4,5-dihydro-1,2,4-triazol-1-yl)acetoxy)-12α-hydroxycholanate 
• 1332599-81-1 C₁₉H₂₉N₅O₂S 
• 1332599-83-3 C₁₆H₂₃N₅O₂S 
• 1332599-70-8 C₁₅H₂₁N₅O₂S 
• 1332599-75-3 C₁₇H₂₅N₅O₂S 
• 1332599-79-7 C₁₇H₂₅N₅O₂S 
• 1332599-68-4 C₁₁H₁₁ClN₄O₂S 
• 1427501-07-2 6-(furan-3-yl)-3-(4-methoxyphenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole 
• 849913-13-9 3-(4-methoxyphenyl)-6-(pyridin-2-yl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole 
• 537017-29-1 3-(4-methoxyphenyl)-6-(pyridin-4-yl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole 
• 577700-42-6 3-(4-methoxyphenyl)-6-(thiophen-2-yl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole 

Relevant articles and documents

An extensive research on aldose reductase inhibitory effects of new 4H-1,2,4-triazole derivatives

Aldose reductase (AR) is a key enzyme, which triggers the excessive accumulation of sorbitol in insulin independent tissues leading to severe diabetes-induced microvascular complications. Substantial evidence has proven that AR inhibition is a well-establ

Development of triazolothiadiazine derivatives as highly potent tubulin polymerization inhibitors: Structure-activity relationship, in vitro and in vivo study

Based on our prior work, we reported the design, synthesis, and biological evaluation of fifty-two new triazolothiadiazine-based analogues of CA-4 and their preliminary structure-activity relationship. Among synthesized compounds, Iab was found to be the most potent derivative possessing IC50 values ranging from single-to double-digit nanomolar in vitro, and also exhibited excellent selectivity over the normal human embryonic kidney HEK-293 cells (IC50 > 100 μM). Further mechanistic studies revealed that Iab significantly blocked tubulin polymerization and disrupted the intracellular microtubule network of A549 cells. Moreover, Iab induced G2/M cell cycle arrest by regulation of p-cdc2 and cyclin B1 expressions, and caused cell apoptosis through up-regulating cleaved PARP and cleaved caspase-3 expressions, and down-regulating of Bcl-2. Importantly, in vivo, Iab effectively suppressed tumor growth of A549 lung cancers in a xenograft mouse model without obvious signs of toxicity, confirming its potential as a promising candidate for cancer treatment.

Symmetrical heterocyclic cage skeleton: Synthesis, urease inhibition activity, kinetic mechanistic insight, and molecular docking analyses

The present study focuses on the design and synthesis of a cage-like organic skeleton containing two triazole rings jointed via imine linkage. These molecules can act as urease inhibitors. The in-vitro urease inhibition screening results showed that the combination of the two triazole skeleton in the cage-like morphology exhibited comparable urease inhibition activity to that of the reference thiourea while the metallic complexation, especially with copper, nickel, and palladium, showed excellent activity results with IC50 values of 0.94 ± 0.13, 3.71 ± 0.61, and 7.64 ± 1.21 (3a–c), and 1.20 ± 0.52, 3.93 ± 0.45, and 12.87 ± 2.11 μM (4a–c). However, the rest of compounds among the targeted series exhibited a low to moderate enzyme inhibition potential. To better understand the compounds’ underlying mechanisms of the inhibitory effect (3a and 4a) and their most active metal complexes (3b and 4b), we performed an enzymatic kinetic analysis using the Lineweaver–Burk plot in the presence of different concentrations of inhibitors to represent the non-competitive inhibition nature of the compounds, 3a, 4a, and 4b, while mixed type inhibition was represented by the compound, 3b. Moreover, molecular docking confirmed the binding interactive behavior of 3a within the active site of the target protein.